Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease
Key Highlights
- ➤Neurocrine (NBIX) initiates Phase 2 study of oral NBI-'567 in Alzheimer's disease
- ➤Phase 2 trial will enroll approximately 135 adults with mild to moderate Alzheimer's
- ➤NBI-'567 will be tested at high and low once-daily doses against placebo
- ➤Study measures cognition, safety, tolerability, and pharmacokinetics over 12 weeks
- ➤Neurocrine's muscarinic pipeline includes direclidine in Phase 3 for schizophrenia
Expert Statements
Eiry W. Roberts, Chief Medical Officer of Neurocrine Biosciences
“As a defining characteristic of Alzheimer's disease, cognitive impairment affects memory, attention, and other thinking abilities that significantly impact daily functioning”
Eiry W. Roberts, Chief Medical Officer of Neurocrine Biosciences
“The advancement of NBI-'567 reflects our commitment to delivering new treatment options for this vulnerable population, in addition to our broader strategy to explore the potential of selectively targeting muscarinic receptors across a range of neurological and psychiatric conditions.”
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease PR Newswire
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in adults with mild to moderate Alzheimer's disease. NBI-'567 is an orally administered, M1/M4 (M1 preferring) selective muscarinic agonist being evaluated as an adjunctive treatment for cognitive impairment in Alzheimer's disease.
Get started
Create a free account to read the full story.